Cargando…

Feasibility of abbreviated cycles of immunochemotherapy for completely resected limited-stage CD20+ diffuse large B-cell lymphoma (CISL 12-09)

BACKGROUND: The appropriate number of chemotherapy cycles for limited stage diffuse large B-cell lymphoma (DLBCL) patients without gross residual lesions after complete resection, has not been specifically questioned. We performed a multicenter, single-arm, phase 2 study to investigate the feasibili...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoon, Dok Hyun, Sohn, Byeong Seok, Oh, Sung Yong, Lee, Won-Sik, Lee, Sang Min, Yang, Deok-Hwan, Huh, Jooryung, Suh, Cheolwon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5355104/ https://www.ncbi.nlm.nih.gov/pubmed/28076329 http://dx.doi.org/10.18632/oncotarget.14531

Ejemplares similares

Abbreviated chemotherapy for limited-stage diffuse large B-cell lymphoma after complete resection
por: Jo, Jungmin, et al.
Publicado: (2014)

The Consortium for Improving Survival of Lymphoma (CISL): recent achievements and future perspective
por: Suh, Cheolwon, et al.
Publicado: (2017)

Intraocular lymphoma in Korea: the Consortium for Improving Survival of Lymphoma (CISL) study
por: Lee, Seul, et al.
Publicado: (2015)

Intestinal Diffuse Large B-Cell Lymphoma: An Evaluation of Different Staging Systems
por: Hwang, Hee Sang, et al.
Publicado: (2014)

Prognostic value of immunohistochemical algorithms in gastrointestinal diffuse large B-cell lymphoma
por: Hwang, Hee Sang, et al.
Publicado: (2013)

EBV-positive diffuse large B-cell lymphoma of the elderly with aberrant expression of CD3 and TIA-1
por: Lee, Miji, et al.
Publicado: (2013)

Modified Number of Extranodal Involved Sites as a Prognosticator in R-CHOP-Treated Patients with Disseminated Diffuse Large B-Cell Lymphoma
por: Yoo, Changhoon, et al.
Publicado: (2010)

Addition of rituximab to the CHOP regimen has no benefit in patients with primary extranodal diffuse large B-cell lymphoma
por: Jang, Geundoo, et al.
Publicado: (2011)

Prognostic Impact of Age at the Time of Diagnosis in Korean Patients with Diffuse Large B-cell Lymphoma in the Rituximab Era: A Single Institution Study
por: Hwang, Hee Sang, et al.
Publicado: (2021)

Diffuse Large B-Cell Lymphoma with Involvement of the Breast and Testis in a Male Patient
por: Choi, Eunji, et al.
Publicado: (2015)

Cluster Containing More Than 20 CD3-Positive Cells in Bone Marrow Biopsy Is a Candidate Prognostic Indicator in Peripheral T-Cell Lymphoma, Not Otherwise Specified
por: Shim, Hyoeun, et al.
Publicado: (2019)

Organ-specific considerations for marginal zone lymphomas in Korea, based on Consortium for Improving Survival of Lymphoma (CISL) and Korean clinical studies
por: Oh, Sung Yong, et al.
Publicado: (2019)

CD163 Expression Was Associated with Angiogenesis and Shortened Survival in Patients with Uniformly Treated Classical Hodgkin Lymphoma
por: Koh, Young Wha, et al.
Publicado: (2014)

Treatment of primary testicular diffuse large B cell lymphoma without prophylactic intrathecal chemotherapy: a single center experience
por: Kim, Jeongseok, et al.
Publicado: (2014)

A Case of Primary Adrenal Diffuse Large B-cell Lymphoma Achieving Complete Remission with Rituximab-CHOP Chemotherapy
por: Kim, Kyung Min, et al.
Publicado: (2009)

Phase II study of R–CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study
por: Oh, Sung Yong, et al.
Publicado: (2019)

Prognostic factors in primary diffuse large B-cell lymphoma of adrenal gland treated with rituximab-CHOP chemotherapy from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Yu Ri, et al.
Publicado: (2012)

Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008)
por: Yoon, Dok Hyun, et al.
Publicado: (2016)

First-Line Treatment for Primary Breast Diffuse Large B-Cell Lymphoma Using Immunochemotherapy and Central Nervous System Prophylaxis: A Multicenter Phase 2 Trial
por: Yhim, Ho-Young, et al.
Publicado: (2020)

Current Treatment Patterns and the Role of Upfront Autologous Stem Cell Transplantation in Patients with Peripheral T-Cell Lymphoma: A Korean Nationwide, Multicenter Prospective Registry Study (CISL 1404)
por: Cho, Hyungwoo, et al.
Publicado: (2023)

Primary central nervous system lymphoma: a new prognostic model for patients with diffuse large B-cell histology
por: Ahn, Yongchel, et al.
Publicado: (2017)

Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study
por: Yhim, Ho-Young, et al.
Publicado: (2010)

Sequential heart and autologous stem cell transplantation for light-chain cardiac amyloidosis
por: Huh, Jin-Young, et al.
Publicado: (2017)

Primary mediastinal large B-cell lymphoma: a single-center experience in Korea
por: Ahn, Heui June, et al.
Publicado: (2014)

Autologous stem cell transplantation for diffuse large B-cell lymphoma with residual extranodal involvement
por: Ko, Ock Bae, et al.
Publicado: (2008)

Clinical features and outcomes in patients with human immunodeficiency virus-negative, multicentric Castleman's disease: a single medical center experience
por: Seo, Seyoung, et al.
Publicado: (2014)

Upward trend in follicular lymphoma among the Korean population: 10-year experience at a large tertiary institution
por: Kim, Meejeong, et al.
Publicado: (2021)

A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomas
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Clinical characteristics, treatment, and outcome of primary rectal lymphoma: a single center experience of 16 patients
por: Jeong, Jae Ho, et al.
Publicado: (2017)

GLUT1 as a Prognostic Factor for Classical Hodgkin’s Lymphoma: Correlation with PD-L1 and PD-L2 Expression
por: Koh, Young Wha, et al.
Publicado: (2017)

Yttrium-90 ibritumomab tiuxetan plus busulfan, cyclophosphamide, and etoposide (BuCyE) versus BuCyE alone as a conditioning regimen for non-Hodgkin lymphoma
por: Jo, Jae-Cheol, et al.
Publicado: (2012)

Reappraisal of the prognostic value of Epstein-Barr virus status in monomorphic post-transplantation lymphoproliferative disorders–diffuse large B-cell lymphoma
por: Kim, Jwa Hoon, et al.
Publicado: (2021)

Multicenter retrospective analysis of 581 patients with primary intestinal non-hodgkin lymphoma from the Consortium for Improving Survival of Lymphoma (CISL)
por: Kim, Seok Jin, et al.
Publicado: (2011)

Treatment outcomes of dose-attenuated CHOP chemotherapy in elderly patients with peripheral T cell lymphoma
por: Choi, Eun-Ji, et al.
Publicado: (2017)

Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era
por: Seo, Seyoung, et al.
Publicado: (2016)

Expression of CD99 in Multiple Myeloma: A Clinicopathologic and Immunohistochemical Study of 170 Cases
por: Shin, Su-Jin, et al.
Publicado: (2014)

Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving Survival of Lymphoma (CISL) Study
por: Kim, Yu Ri, et al.
Publicado: (2023)

Prognostic Value of Immunohistochemical Biomarkers at Different Cut-off Values in Patients with Diffuse Large B-cell Lymphoma Treated with CHOP Chemotherapy
por: Oh, Sukjoong, et al.
Publicado: (2011)

Relapse pattern and prognostic factors for patients with primary central nervous system lymphoma
por: Kim, Jeong Eun, et al.
Publicado: (2012)

Prognostic Significance of Absolute Lymphocyte Count/Absolute Monocyte Count Ratio at Diagnosis in Patients with Multiple Myeloma
por: Shin, Su-Jin, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_j5pnm13e2vdgp2vif18bomuqgi